Oncology Central

High-dose IL-2 for metastatic renal cell carcinoma: can the first antitumor immunotherapy be reinvented?

0

Immunotherapy for the treatment of cancer holds the unique promise of durable, systemic antitumor responses capable of targeting malignant disease throughout the body. Just 8 years after the discovery of IL-2 [1], this promise was first fulfilled in a small clinical trial utilizing systemic high-dose IL-2 (HD IL-2) demonstrating a complete response in a metastatic melanoma patient who was cured of all malignant disease and has remained disease free for more than 29 years [2,3].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.